Guardant Health AMEA

The official X account of Guardant Health AMEA. Content on this account is meant for healthcare professionals only.

[Guardant Health AMEA @GuardantAMEA]

We are pleased to announce that Guardant Health Japan has received approval from Ministry of Health, Labour and Welfare of Japan for Guardant360® CDx liquid biopsy as a companion diagnostic for trastuzumab deruxtecan (recombinant) in advanced solid tumors with ERBB2 copy number alteration (HER2 gene amplification positive). Daiichi Sankyo Co., Ltd. is currently seeking partial approval changes for this use.

Amplification of the ERBB2 gene, a known oncogenic driver, is more commonly observed in breast and gastric cancers in Japan, but can be present across solid tumors. In an analysis of 50,000 patient cases that underwent cancer genomic profiling conducted by National Cancer Center Japan (February 2024), ERBB2 amplifications were identified as the most frequent type of copy number alteration.

Anti-HER2 therapy is currently used in Japan to treat breast, gastric, lung, salivary gland, and colorectal cancers. However, it is not used for other solid cancers showing ERBB2 copy number alterations (HER2 gene amplification positive). Advancing the insurance coverage process for Guardant360® CDx will expand access to treatment options for more patients living with solid tumors.

See full press release in Japanese: https://t.co/o2KWQLO48l

Visit us at https://t.co/VHt7zlTalh to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only.

[Guardant Health AMEA @GuardantAMEA]

Minimal Residual Disease (MRD) testing, for both MRD detection and surveillance monitoring, is critical to improving patient outcomes and reshaping care for early-stage cancer.

We invite oncologists and healthcare professionals to join us for a webinar to unpack case studies, share the latest MRD evidence and reconsider how we think about MRD testing.

Sign up today at https://t.co/liN6NSFwUF

[Guardant Health AMEA @GuardantAMEA]

We were pleased to join the recent Taiwan conference on The Clinical Application of Liquid Biopsy in Solid Tumors: Now and Future. Conference participants called for the inclusion of liquid biopsy in Taiwan’s National Health Insurance to ensure that cancer patients have faster access to the most appropriate treatment.

Read more: https://t.co/Tt8nmQdctt

[Guardant Health AMEA @GuardantAMEA]

Behind every cancer treatment decision is timely, precise insight. As treatment options expand, understanding the full genomic landscape of breast cancer is key to making informed decisions.

Hear from Dr. @Shaheenah1 in our continuing Hear from the Expert series this #BreastCancerAwarenessMonth

[Guardant Health AMEA @GuardantAMEA]

Proud to collaborate with Taiho Pharmaceutical to discover new biomarker signatures for early-stage cancer, powered by our real-world data platform GuardantINFORM.

We welcome pharma partners to join us in harnessing data-driven innovation to shape the future of precision oncology.

Link to press release: https://t.co/nL8UQrAy8r

[Guardant Health AMEA @GuardantAMEA]

✨ Happy Diwali from all of us at Guardant Health! ✨

May the light of Diwali shine as brightly as the hope we share in every step towards better health.

[Guardant Health AMEA @GuardantAMEA]

Every patient’s journey with breast cancer is unique – and every story helps us care better. In our continuing Hear from the Expert series, Dr @herdeeluna shares how comprehensive genomic profiling helps tailor treatments to each patient’s needs.

#BreastCancerAwarenessMonth #PrecisionMedicine

[Guardant Health AMEA @GuardantAMEA]

Looking forward to #ESMO25, where clinicians will share results from research collaborations with Guardant Health AMEA, and new real-world data across solid tumor types.

A heartfelt thank you to the researchers and collaborators @JiaJennyLiu, @docrohatgi Nir Peled, Amit Rauthan, Shota Fukuoka, @kobashin0117, @Hiroki_Osumi, and Seiichiro Mitani.

We remain committed to collaborating with clinicians to advance real-world evidence in precision oncology.

[Guardant Health AMEA @GuardantAMEA]

📢 Oncologists: this Breast Cancer Awareness Month, join our webinar on Clinical Utility of Comprehensive Genomic Profiling in Advanced Breast Cancer Management. Hear from leading clinical experts on how CGP continues to shape personalized care in advanced breast cancer.

📅When: October 15, 2025
⏰ Time: 9:30 PM – 11:00 PM (GMT +8)

Register: https://t.co/yD7NAA6jy4

[Guardant Health AMEA @GuardantAMEA]

At #BestofASCOPH25, Dr. Arthur Lui emphasized the value of CGP in colorectal cancer care, and shared how integrating tissue & liquid CGP into routine care informs first-line treatment and identifies resistance in later lines.

[Guardant Health AMEA @GuardantAMEA]

🚀 Innovation is transforming breast cancer care!

This #BreastCancerAwarenessMonth, our Hear from the Expert series will share perspectives of leading oncologists on the role of precision oncology in advancing breast cancer care..

Join us this October as we spotlight their voices.

[Guardant Health AMEA @GuardantAMEA]

📢Oncologists: join our webinar on Multiomics in Precision Oncology on Oct 8 (9–10:30 PM GMT+8).

Learn how multiomic approaches with a tissue test delivers deeper insights to support decision making, even when working with limited biopsy samples in advanced solid tumors.

Register here: https://t.co/7OGdrBOKmn

[Guardant Health AMEA @GuardantAMEA]

We joined #IICAsia2025 to discuss the future of health insurance. Key takeaway: insurers must go beyond critical illness payouts – partnering with people on their health journey. Collaboration across insurers, healthcare providers, pharma and medtech is key to empowering healthier lives.

[Guardant Health AMEA @GuardantAMEA]

Guardant Health AMEA applauds @APEC and the member economies’ commitment to integrated cancer care – and we look forward to partnering with governments and health systems to advance cancer control and improve outcomes.

📄: https://t.co/6rtCwHEOUu

[Guardant Health AMEA @GuardantAMEA]

📍We also hosted a booth at the event, showcasing how liquid biopsy guides personalized treatment, which may lead to better outcomes.

Big thanks to Manulife Singapore for hosting an inspiring symposium!

#Longevity #InnovationInHealthcare #CancerCare #HealthTech

[Guardant Health AMEA @GuardantAMEA]

🚀 How is technology transforming cancer care?

We joined Manulife Singapore’s Longevity Symposium for a powerful panel on Rewriting Cancer Care, exploring how innovations like liquid biopsies, AI diagnostics & robotic surgery are reshaping the patient journey.

[Guardant Health AMEA @GuardantAMEA]

With liquid biopsy, oncologists can determine the right drug for the right patient at the right time with a simple blood draw” – shared Dr. Nantha Kumar, Head of Medical Affairs, AMEA